The products acquired from Vybion complement the growing portfolio of highly specialized biologicals that the company manufactures and distributes to the diagnostic, pharmaceutical and research markets, said Meridian. They will be used in the manufacture of tests for the diagnosis of infectious diseases and in the monitoring of human protein levels in hepatitis, HIV, HSV and cardiac disease.
This acquisition adds important technologies and capabilities to Meridian’s life science business and will add to Meridian’s expanding life science brands, Biodesign, OEM Concepts, Viral Antigens, and Meridian Biologics. The acquired technologies will add proprietary manufacturing know-how and access to important patent licenses for the development and production of recombinant proteins, an emerging technology in life sciences, the company said.
Through this acquisition and development of advanced enabling technologies, Meridian continues to expand its life science business to support and service researchers, diagnostic test manufacturers, as well as biopharmaceutical and biotechnology companies.
Richard Eberly, president of Meridian Life Science, said: “This acquisition adds key capabilities and revenues to our life science business. The strategic fit is consistent with Meridian’s goals of expanding its life science business through internal growth and acquisitions.”